Osaic Holdings’s Apogee Therapeutics APGE Stock Holding History

Osaic Holdings’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$93.7K	Sell	706 -304	-30%	-$27.4K	﹤0.01%	5007
2026 Q1	$85K	Buy	1,010 +51	+5%	+$3.7K	﹤0.01%	4802
2025 Q4	$72.4K	Buy	959 +410	+75%	+$25.8K	﹤0.01%	4973
2025 Q3	$20.4K	Buy	549 +301	+121%	+$11.5K	﹤0.01%	5915
2025 Q2	$10.8K	Buy	248 +246	+12,300%	+$9.36K	﹤0.01%	6103
2025 Q1	$75	Sell	2 -12	-86%	-$464	﹤0.01%	7257
2024 Q4	$634	Sell	14 -12	-46%	-$612	﹤0.01%	6958
2024 Q3	$1.53K	Sell	26 -3,956	-99%	-$190K	﹤0.01%	6710
2024 Q2	$157K	Buy	+3,982	New	+$193K	﹤0.01%	3765

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Osaic Holdings's APGE Position: Q2 2026 in Review

Osaic Holdings reduced its Apogee Therapeutics (APGE) stake by 30% in Q2 2026, selling an estimated $27.4K and leaving 706 shares worth $93.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5007.

Osaic Holdings first reported a position in APGE in Q2 2024 and has held it in 9 quarters since. The position peaked at $157K in Q2 2024. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Osaic Holdings held 706 shares of Apogee Therapeutics worth $93.7K as of Q2 2026.
Osaic Holdings sold 304 Apogee Therapeutics shares in Q2 2026, an estimated $27.4K.
Apogee Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #5007 holding.
Osaic Holdings first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 9 quarters since.
Osaic Holdings's Apogee Therapeutics position peaked at $157K in Q2 2024.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.